2. Academic Validation
  3. Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1

Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1

  • J Transl Med. 2023 Aug 16;21(1):549. doi: 10.1186/s12967-023-04400-3.
Ruijiao Chen # 1,  Xiaopeng Hao # 2,  Jingyuan Chen 2,  Changyue Zhang 1 3,  Huixia Fan 2,  Fuming Lian 2,  Xiaochuan Chen 4,  Chao Wang 5,  Yong Xia 6 7
Affiliations

Affiliations

  • 1 Medical Laboratory of Jining Medical University, Jining Medical University, Jining, 272067, Shandong, China.
  • 2 Institute of Precision Medicine, Jining Medical University, No. 133 Hehua Road, Taibaihu District, Jining, 272067, Shandong, China.
  • 3 School of Pharmacy, Binzhou Medical University, Yantai, 264003, Shandong, China.
  • 4 Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu, 610064, China. [email protected].
  • 5 Department of Urology, Jining No. 1 People's Hospital, Jining, 272106, Shandong, China. [email protected].
  • 6 Medical Laboratory of Jining Medical University, Jining Medical University, Jining, 272067, Shandong, China. [email protected].
  • 7 Institute of Precision Medicine, Jining Medical University, No. 133 Hehua Road, Taibaihu District, Jining, 272067, Shandong, China. [email protected].
  • # Contributed equally.
PMID: 37587470 DOI: 10.1186/s12967-023-04400-3
Abstract

Background: Bladder Cancer is a urological carcinoma with high incidence, among which muscle invasive bladder Cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency Anticancer effect, but its Anticancer function and mechanism on bladder Cancer have not been studied.

Methods: To examine the Anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the Anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed.

Results: JorA inhibited the proliferation of MIBC cells, and the IC50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in "cancer-related pathways" and "EGFR-related signaling pathways", which mainly manifested by inhibiting cell proliferation and promoting cell Apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and Topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were - 8.153 and - 7.264 kcal/mol, respectively).

Conclusions: The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder Cancer therapy.

Keywords

Apoptosis; Jorunnamycin A; Molecular docking; Muscle invasive bladder cancer; Proliferation; Proteomics; Transcriptomics.

Figures
Products